Patent · US Active

Intralymphatic delivery of hyaluronan nanoparticle for cancer metastasis

US10632081B2 · kind B2 · utility

0Cited by

6References

21Claims

0Family size

Assignee

Industrial Technology Research Institute · TW

Inventors

Chih-Peng LIU · Hsinchu, TW
Ya-Chin Lo · Taichung, TW
Ming-Cheng Wei · Taoyuan, TW
Maggie Lu · Guoxing Township, TW
Shuen-Hsiang Chou · Gongguan, TW
Shih-Ta Chen · New Taipei, TW
Hsiang-Wen Tseng · New Taipei, TW

Key dates

Filing date	Apr 29, 2016
Grant date	Apr 28, 2020
Priority date	—
Expiry date	Jan 5, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed is an intralymphatic delivery method for treating lymphatic cancer using hyaluronan nanoparticles. These nanoparticles include a hyaluronic acid derivative and a platinum compound. The hyaluronan derivative includes hyaluronic acid, modified histidine and optionally one or more of a polymer or a C4-C20 alkyl. The hyaluronic acid derivative may include linking group(s) that connect the polymer or the C4-C20 alkyl to the hyaluronic acid. The platinum compound includes dichloro(1,2-diaminocyclohexane) platinum (DACHPt), cisplatin and oxaliplatin. This intralymphatic delivery method offers significant advantages for the use of platinum medicines in treating lymphatic cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.